Management of stage T1 tumors of the bladder: Internat

Urology
66, 108-125
DOI: 10.1016/j.urology.2005.08.066

Citation Report

#	Article	IF	Citations
1	Change of Sexual Function in Patients Before and After Ho:YAG Laser Enucleation of the Prostate. Journal of Andrology, 2006, 28, 259-261.	2.0	41
2	Radical cystectomy after bacillus Calmette-GuÃ©rin for high-risk Ta, T1, and carcinoma in situ: Defining the risk of initial bladder preservation. Urology, 2006, 67, 737-741.	0.5	41
3	The Role of the Surgeon and Transurethral Resection in the Treatment of Superficial Bladder Cancer. Scientific World Journal, The, 2006, 6, 2626-2631.	0.8	7
4	Obesity, adipokines, and prostate cancer (Review). International Journal of Oncology, 2006, 28, 737.	1.4	32
5	Laser treatment of symptomatic benign prostatic hyperplasia. World Journal of Urology, 2006, 24, 410-417.	1.2	20
6	Treatment options for BCG failures. World Journal of Urology, 2006, 24, 481-487.	1.2	79
7	The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detection and Prevention, 2006, 30, 269-275.	2.1	23
8	Techniques and Long-Term Results of Surgical Procedures for BPH. European Urology, 2006, 49, 970-978.	0.9	254
10	Current Role of Lasers in the Treatment of Benign Prostatic Hyperplasia (BPH). European Urology, 2006, 49, 961-969.	0.9	207
11	Holmium Laser Enucleation of the Prostate Versus Open Prostatectomy for Prostates >70g: 24-Month Follow-up. European Urology, 2006, 50, 563-568.	0.9	331
13	American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity. Ca-A Cancer Journal for Clinicians, 2006, 56, 254-281.	157.7	1,021
14	Complications of Urologic Surgery and Practice. , 0, , .		4
15	Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis. PLoS Medicine, 2007, 4, e284.	3.9	79
16	Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiologic Reviews, 2007, 29, 88-97.	1.3	199
17	Prognostic Effect of DNA Aneuploidy from Bladder Washings in Superficial Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 979-983.	1.1	7
18	Instrumental treatments for benign prostatic obstruction. Current Opinion in Urology, 2007, 17, 17-21.	0.9	14
19	Holmium laser treatment of benign prostatic hyperplasia: an update. Current Opinion in Urology, 2007, 17, 27-31.	0.9	27
20	Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Current Opinion in Urology, 2007, 17, 352-357.	0.9	27

#	Article	IF	Citations
21	Preliminary results on diode-laser assisted vaporization of prostate tissue. , 2007, , .		0
22	Lack of Progress in Early Diagnosis of Bladder Cancer. Urology, 2007, 69, 270-274.	0.5	23
23	Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 338-340.	0.8	22
24	Technique of TUR of Bladder Tumours: Value of Repeat TUR and Random Biopsies. EAU-EBU Update Series, 2007, 5, 139-144.	0.7	5
25	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer, 2007, 43, 1180-1187.	1.3	29
26	Treatment of Intermediate-Risk Nonâ€"Muscle-Invasive Bladder Cancer (NMIBC). European Urology Supplements, 2007, 6, 800-808.	0.1	7
30	Re: Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy?. Journal of Urology, 2007, 178, 352-352.	0.2	1
31	Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male, 2007, 10, 189-196.	0.9	92
32	Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy?. Journal of Urology, 2007, 177, 75-79.	0.2	136
34	The Characteristics of Prostate Cancer with Metabolic Syndrome in Korean Men. Korean Journal of Urology, 2007, 48, 585.	0.2	3
35	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. International Journal of Cancer, 2007, 121, 791-795.	2.3	44
36	Simultaneous transurethral cystolithotripsy with holmium laser enucleation of the prostate: a prospective feasibility study and review of literature. BJU International, 2007, 99, 595-600.	1.3	49
37	Analysis of progression and survival after 10â€ƒyears of a randomized prospective study comparing mitomycin-C and bacillus Calmette-GuÃ©rin in patients with high-risk bladder cancer. BJU International, 2007, 99, 817-820.	1.3	42
38	Peri-operative complications of holmium laser enucleation of the prostate: experience in the first 280 patients, and a review of literature. BJU International, 2007, 100, 94-101.	1.3	169
39	Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100â€ƒmL. BJU International, 2007, 100, 593-598.	1.3	118
40	Body mass index influences prostateâ€specific antigen in men younger than 60â€ƒyears of age. International Journal of Urology, 2007, 14, 1009-1012.	0.5	22
41	Safety and Effectiveness of Photoselective Vaporization of the Prostate (PVP) in Patients on Ongoing Oral Anticoagulation. European Urology, 2007, 51, 1031-1041.	0.9	212
42	Holmium Laser Enucleation versus Transurethral Resection of the Prostate: 3-Year Follow-Up Results of a Randomized Clinical Trial. European Urology, 2007, 52, 1456-1464.	0.9	216

#	Article	IF	Citations
43	Obesity and Prostate Cancer: Epidemiology and Clinical Implications. European Urology, 2007, 52, 331-343.	0.9	209
44	The Diode Laser: A Novel Side-Firing Approach for Laser Vaporisation of the Human Prostateâ€"Immediate Efficacy and 1-Year Follow-Up. European Urology, 2007, 52, 1717-1722.	0.9	59
45	It Is Time to Abandon the â€œSuperficialâ€•in Bladder Cancer. European Urology, 2007, 52, 1564-1565.	0.9	33
46	Advances in the Management of Superficial Bladder Cancer. Seminars in Oncology, 2007, 34, 85-97.	0.8	36
47	Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens. Journal of Clinical Oncology, 2007, 25, 3596-3602.	0.8	89
48	Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes and Control, 2007, 18, 375-384.	0.8	11
49	Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: What makes better economic sense?. Current Prostate Reports, 2007, 5, 169-177.	0.1	0
50	Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: What makes better economic sense?. Current Urology Reports, 2007, 8, 289-297.	1.0	10
51	Laser prostatic surgery: An update. African Journal of Urology, 2008, 14, 1-14.	0.1	3
52	The association between metabolic syndrome and prostateâ€specific antigen levels. International Journal of Urology, 2008, 15, 905-909.	0.5	21
53	Influence of prostate size on the outcome of holmium laser enucleation of the prostate. BJU International, 2008, 101, 1536-1541.	1.3	71
54	Holmium laser prostatic resection for patients presenting with acute urinary retention. BJU International, 2008, 102, 1623-1628.	1.3	10
55	Nerve-Sparing Radical Retropubic Prostatectomy in Patients Previously Submitted to Holmium Laser Enucleation of the Prostate for Bladder Outlet Obstruction Due to Benign Prostatic Enlargement. European Urology, 2008, 53, 1180-1185.	0.9	35
56	Holmium Laser Enucleation of the Prostate versus Open Prostatectomy for Prostates Greater than 100 Grams: 5-Year Follow-Up Results of a Randomised Clinical Trial. European Urology, 2008, 53, 160-168.	0.9	482
57	Editorial Comment on: Holmium Laser Enucleation of the Prostate versus Open Prostatectomy for Prostates Greater than 100grams: 5-Year Follow-up Results of a Randomised Clinical Trial. European Urology, 2008, 53, 166-167.	0.9	0
58	Prognostic Factors in Patients with Nonâ€"Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-GuÃ©rin: Multivariate Analysis of Data from Four Randomized CUETO Trials. European Urology, 2008, 53, 992-1002.	0.9	220
59	Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients. European Urology, 2008, 53, 599-606.	0.9	115
60	Editorial Comment on: Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients. European Urology, 2008, 53, 604-605.	0.9	0

#	Article	IF	Citations
61	Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy. Urology, 2008, 72, 1102-1105.	0.5	79
62	Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Review of Anticancer Therapy, 2008, 8, 1103-1110.	1.1	16
63	Arguments against the Use of Fluorescence for the Diagnosis of Nonâ€"Muscle-Invasive Bladder Tumours (NMIBT). European Urology Supplements, 2008, 7, 430-433.	0.1	8
64	Improving Transurethral Resection of Bladder Tumour: The Gold Standard for Diagnosis and Treatment of Bladder Tumours. European Urology Supplements, 2008, 7, 524-528.	0.1	19
65	Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations. European Urology Supplements, 2008, 7, 637-650.	0.1	21
66	Clinical Practice Recommendations for the Management of Nonâ€"Muscle Invasive Bladder Cancer. European Urology Supplements, 2008, 7, 651-666.	0.1	28
67	Multiplicity and History Have a Detrimental Effect on Survival of Patients With T1G3 Bladder Tumors Selected for Conservative Treatment. Journal of Urology, 2008, 180, 886-891.	0.2	9
69	Clinical Value of PTEN in Patients with Superficial Bladder Cancer. Urologia Internationalis, 2008, 80, 264-269.	0.6	14
70	BPH Procedural Treatment: The Case for Value-Based Pay for Performance. Advances in Urology, 2008, 2008, 1-6.	0.6	2
71	Intravesical Bacillus Calmette-GuÃ©rin Therapy for T1 Superficial Bladder Cancer. Urologia Internationalis, 2008, 80, 74-79.	0.6	8
72	Influence of Body Mass Index and Total Testosterone Level on Biochemical Recurrence Following Radical Prostatectomy. Japanese Journal of Clinical Oncology, 2008, 38, 129-133.	0.6	16
73	Holmium Laser Enucleation of the Prostate Is the Single Best Treatment for Benign Prostatic Hyperplasia Refractory to Medication. Journal of Endourology, 2008, 22, 2113-2116.	1.1	8
74	Review:Intracavitary Radioimmunotherapy to Treat Solid Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 92-107.	0.7	22
75	Percutaneous versus Transurethral Cystolithotripsy. Journal of Endourology, 2009, 23, 237-242.	1.1	42
76	Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1350-1356.	1.1	55
77	The relationship between the reproducibility of holmium laser enucleation of the prostate and prostate size over the learning curve. Prostate Cancer and Prostatic Diseases, 2009, 12, 281-284.	2.0	19
78	Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer and Prostatic Diseases, 2009, 12, 259-263.	2.0	124
79	Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 808-815.	1.1	25

#	Article	IF	Citations
80	Patient outcomes in the acute recovery phase following robotic-assisted prostate surgery: A prospective study. International Journal of Nursing Studies, 2009, 46, 442-449.	2.5	5
81	Single Postoperative Instillation of Gemcitabine in Patients with Non-muscle-invasive Transitional Cell Carcinoma of the Bladder: A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Study. European Urology, 2009, 56, 495-503.	0.9	93
82	The prognostic value of cytology and fluorescence in situ hybridization in the followâ€up of nonmuscleâ€invasive bladder cancer after intravesical Bacillus Calmetteâ€Guã©rin therapy. International Journal of Cancer, 2009, 124, 2899-2904.	2.3	98
83	High-power diode laser at 980Ânm for the treatment of benign prostatic hyperplasia: exÂvivo investigations on porcine kidneys and human cadaver prostates. Lasers in Medical Science, 2009, 24, 172-178.	1.0	47
84	Bladder cancer: new TUR techniques. World Journal of Urology, 2009, 27, 309-312.	1.2	56
85	Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology, 2009, 22, S70-S95.	2.9	166
86	Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. International Journal of Urology, 2009, 16, 676-681.	0.5	9
87	Pathological stage review is indicated in primary pT1 bladder cancer. BJU International, 2010, 106, 206-211.	1.3	46
88	Holmium Laser Enucleation of Prostate in Patients With Prostate Size â‰60 cm3. Urology, 2009, 73, 95-99.	0.5	12
89	Holmium Laser Enucleation of Prostate: Outcome and Complications of Self-taught Learning Curve. Urology, 2009, 73, 1042-1048.	0.5	124
90	Pathological Upstaging During Radical Cystectomy Is Associated With Worse Recurrence-free Survival in Patients With Bacillus Calmette-Guerin-refractory Bladder Cancer. Urology, 2009, 74, 1276-1280.	0.5	37
92	Avances sobre la influencia del tejido adiposo en el adenocarcinoma de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2009, 33, 242-248.	0.3	4
93	Holmium Laser Applications of the Prostate. Urologic Clinics of North America, 2009, 36, 485-495.	0.8	36
95	Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Current Opinion in Urology, 2009, 19, 38-43.	0.9	45
96	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anti-Cancer Drugs, 2010, 21, 101-106.	0.7	19
97	Bladder Cancer: A Review of Non-Muscle Invasive Disease. Cancer Control, 2010, 17, 256-268.	0.7	75
98	Bladder Cancer in 2010: How Far have We Come?. Ca-A Cancer Journal for Clinicians, 2010, 60, 244-272.	157.7	291
99	Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience. European Urology, 2010, 57, 843-849.	0.9	253

#	Article	IF	Citations
100	Editorial Comment on: Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience. European Urology, 2010, 57, 849.	0.9	3
101	An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) Tj ETQq1 1 0.784314 rgBT /Ov	0.9	169
102	Bacillus Calmette-GuÃ©rin Is Superior to a Combination of Epirubicin and Interferon-Î±2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study. European Urology, 2010, 57, 25-31.	0.9	88
103	Re: Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine?. European Urology, 2010, 57, 730-731.	0.9	0
104	Re: Prostate-sparing cystectomy: long-term oncological results. European Urology, 2010, 57, 731-732.	0.9	0
105	Patterns of questionable quality care in nonmuscle invasive bladder cancer. Cancer, 2010, 116, 2508-2510.	2.0	3
106	Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer, 2010, 116, 5650-5658.	2.0	18
107	The relationship between adiposity and gleason score in men with localized prostate cancer. Prostate, 2010, 70, 1683-1691.	1.2	4
108	Risk factors for positive findings in patients with highâ€grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmetteâ€GuÃ©rin therapy and the decision for a repeat TUR. BJU International, 2010, 105, 202-207.	1.3	36
109	HOLMIUM LASER ENUCLEATION OF THE PROSTATE: MODIFIED TECHNICAL ASPECTS. BJU International, 2010, 105, 584-585.	1.3	44
110	Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: Effectiveness, Safety, and Overcoming of the Learning Curve. Korean Journal of Urology, 2010, 51, 619.	1.2	36
111	Outcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels. Korean Journal of Urology, 2010, 51, 21.	1.2	7
112	Current Laser Treatments for Benign Prostatic Hyperplasia. Korean Journal of Urology, 2010, 51, 737.	1.2	17
113	The Metabolic Syndrome and the Risk of Prostate Cancer under Competing Risks of Death from Other Causes. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2088-2096.	1.1	68
114	Is Repeat Transurethral Resection Effective and Necessary in Patients with T1 Bladder Carcinoma?. Urologia Internationalis, 2010, 85, 276-280.	0.6	16
115	Holmium Laser Enucleation of the Prostate for Prostates Larger Than 175 Grams. Journal of Endourology, 2010, 24, 433-437.	1.1	75
116	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1891-1902.	1.1	8
117	Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten^{+/-}preclinical mouse model. Cell Cycle, 2010, 9, 1824-1829.	1.3	13

#	Article	IF	Citations
119	The Role of Tumor-Free Status in Repeat Resection Before Intravesical Bacillus Calmette-Guerin for High Grade Ta, T1 and CIS Bladder Cancer. Journal of Urology, 2010, 183, 2161-2164.	0.2	39
120	Intravesical therapy for bladder cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 947-958.	0.9	42
121	Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1903-1916.	1.1	8
122	Evaluation of Second-Look Transurethral Resection in Restaging of Patients with Nonmuscle-Invasive Bladder Cancer. Journal of Endourology, 2010, 24, 2047-2050.	1.1	35
123	Holmium Laser Enucleation of the Prostate: Initial Report of the First 230 Egyptian Cases Performed in a Single Center. Urology, 2010, 76, 448-452.	0.5	19
124	Higher Body Mass Index Is Associated With Lower Risk of Prostate Cancer Detection Via Multi (â‰¥12)-Core Prostate Biopsy in Korean Men. Urology, 2010, 76, 1063-1066.	0.5	13
125	Indications and Oncologic Outcome of Radical Cystectomy for Urothelial Bladder Cancerâ€. European Urology Supplements, 2010, 9, 10-18.	0.1	14
126	Challenging the EAU Guidelines on Nonâ€“Muscle-Invasive Bladder Cancer (NMIBC): Single Instillation of Chemotherapy After Transurethral Resection of NMIBC and Chemotherapy Versus Bacillus Calmette-GuÃ©rin in Treatment of Intermediate-Risk Tumours. European Urology Supplements, 2010, 9, 406-410.	0.1	13
128	Urological aspects of the metabolic syndrome. Nature Reviews Urology, 2011, 8, 483-494.	1.9	83
129	Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 398-404.	0.8	2
130	Influence of obesity on the incidence and treatment of genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 476-486.	0.8	37
131	Transition in Type of Surgery for Benign Prostatic Hyperplasia: A Multiâ€institutional Study in Japan. LUTS: Lower Urinary Tract Symptoms, 2011, 3, 104-108.	0.6	2
132	A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. Journal of Urology, 2011, 186, 2158-2167.	0.2	247
133	Hiperplasia benigna de prÃ³stata. Medicine, 2011, 10, 5628-5641.	0.0	0
134	Obesity and prostate cancer collateral damage in the battle of the bulge. Frontiers in Bioscience - Scholar, 2011, S3, 594-605.	0.8	11
135	Holmium Laser Enucleation of Prostate for Benign Prostatic Hyperplasia: Seoul National University Hospital Experience. International Neurourology Journal, 2011, 15, 29.	0.5	24
136	Recognition and Treatment of BCG Failure in Bladder Cancer. Scientific World Journal, The, 2011, 11, 602-613.	0.8	24
137	An update on holmium laser enucleation of the prostate and why it has stood the test of time. Current Opinion in Urology, 2011, 21, 31-35.	0.9	9

#	Article	IF	Citations
138	Longâ€term followâ€up of T1 highâ€grade bladder cancer after intravesical bacille Calmetteâ€GuÃ©rin treatment. BJU International, 2011, 107, 540-546.	1.3	37
139	Radical cystectomy for BCG failure: has the timing improved in recent years?. BJU International, 2011, 108, 182-185.	1.3	20
140	BLADDER TUMOURS: TIME FOR A PARADIGM SHIFT?. BJU International, 2011, 107, 1543-1545.	1.3	4
141	JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology, 2011, 18, e1.	0.5	5
142	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. British Journal of Cancer, 2011, 104, 875-881.	2.9	23
143	The Optimal Diagnosis of Urothelial Carcinoma of the Bladder. Current Cancer Therapy Reviews, 2011, 7, 267-271.	0.2	0
144	Holmium Laser Enucleation Versus Bipolar Resection of the Prostate: A Prospective Randomized Study. Which to Choose?. Journal of Endourology, 2011, 25, 1347-1352.	1.1	66
145	Impact of Metabolic Syndrome on Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy. Urologia Internationalis, 2011, 87, 270-275.	0.6	19
146	Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Current Opinion in Urology, 2012, 22, 405-414.	0.9	9
147	Comparison of 120â€“200 W 2â€‰Î¼m Thulium:Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate. Journal of Endourology, 2012, 26, 224-229.	1.1	30
148	The Urinary Tract. , 2012, , .		3
149	The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer and Prostatic Diseases, 2012, 15, 70-74.	2.0	20
150	Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA. Advances in Urology, 2012, 2012, 1-8.	0.6	31
151	Transurethral Vapor Enucleation and Resection of the Prostate with Plasma Vaporization Button Electrode for the Treatment of Benign Prostatic Hyperplasia: A Feasibility Study. Journal of Endourology, 2012, 26, 1264-1266.	1.1	7
152	Follow-up procedures for non-muscle-invasive bladder cancer: an update. Expert Review of Anticancer Therapy, 2012, 12, 1229-1241.	1.1	17
154	High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World Journal of Urology, 2012, 30, 833-840.	1.2	20
155	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2012, 62, 1088-1096.	0.9	67
156	The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer. Journal of Urology, 2012, 187, 310-314.	0.2	85

#	Article	IF	Citations
157	The Management of Bladder Lithiasis in the Modern Era of Endourology. Urology, 2012, 79, 980-986.	0.5	71
158	Prognostic Value of Reninâ€“Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer. Annals of Surgical Oncology, 2012, 19, 3987-3993.	0.7	33
159	Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: A potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry, 2012, 88, 127-133.	2.4	17
161	Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer Cases. Journal of Urology, 2012, 188, 2114-2119.	0.2	28
163	Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-Âµm lasers. Asian Journal of Andrology, 2012, 14, 325-329.	0.8	24
164	Prostate Cancer in Patients with Metabolic Syndrome Is Associated with Low Grade Gleason Score When Diagnosed on Biopsy. Korean Journal of Urology, 2012, 53, 593.	1.2	21
165	Advantages of Robot-Assisted Laparoscopic Radical Prostatectomy in Obese Patients: Comparison with the Open Procedure. Korean Journal of Urology, 2012, 53, 536.	1.2	18
166	A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. European Urology, 2012, 61, 378-384.	0.9	144
167	Reply to Maximilian Burger, Wolfgang Otto, and Arndt Hartmann's Letter to the Editor re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012;61:378â€“84. European Urology, 2012, 61, e33-e34.	0.9	0
168	Reply to Anna Orsola, InÃ©s de Torres and Juan Moroteâ€™s Letter to the Editor re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012:61:378â€“84. European Urology, 2012, 61, e55-e56.	0.9	0
169	Good quality whiteâ€light transurethral resection of bladder tumours (GQâ€WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new nonâ€muscleâ€invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU International, 2012, 109, 1666-1673.	1.3	89
170	120â€W 2â€Âµm thulium:yttriumâ€“aluminiumâ€“garnet vapoenucleation of the prostate: 12â€month followâ€up. BJU International, 2012, 110, 96-101.	1.3	37
171	Prognostic significance of Bacillus Calmetteâ€GuÃ©rin failure classification in nonâ€muscleâ€invasive bladder cancer. BJU International, 2012, 110, E216-21.	1.3	35
172	Prognostic value of molecular markers, subâ€stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU International, 2012, 110, 1169-1176.	1.3	53
173	Risk of subsequent tumour recurrence and stage progression in bacille Calmetteâ€GuÃ©rin relapsing nonâ€muscleâ€invasive bladder cancer. BJU International, 2012, 110, E508-13.	1.3	14
174	Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature. Current Urology Reports, 2013, 14, 620-627.	1.0	16
176	Does obesity affect the accuracy of prostateâ€specific antigen (<scp>PSA</scp>) for predicting prostate cancer among men undergoing prostate biopsy. BJU International, 2013, 112, E265-71.	1.3	26
177	Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 866-870.	0.8	28

#	Article	IF	Citations
178	Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 997-1002.	0.8	50
179	Holmium Laser Enucleation of the Prostate Versus Transurethral Resection of the Prostate: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Endourology, 2013, 27, 604-611.	1.1	167
180	Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opinion on Biological Therapy, 2013, 13, 1371-1385.	1.4	25
181	New Agents for Bacillus Calmette-GuÃ©rinâ€“Refractory Bladder Cancer. Urologic Clinics of North America, 2013, 40, 219-232.	0.8	8
182	Holmium Laser Enucleation of the Prostate for Persistent Lower Urinary Tract Symptoms After Prior Benign Prostatic Hyperplasia Surgery. Urology, 2013, 81, 1025-1029.	0.5	27
183	Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma. Urologic Clinics of North America, 2013, 40, 233-247.	0.8	15
184	Obesity Is Not Associated With Aggressive Pathologic Features or Biochemical Recurrence After Radical Prostatectomy. Urology, 2013, 81, 992-997.	0.5	26
185	Complications and Early Postoperative Outcome in 1080 Patients After Thulium Vapoenucleation of the Prostate: Results at a Single Institution. European Urology, 2013, 63, 859-867.	0.9	119
186	Body Mass Index and Prostate Cancer Severity: Do Obese Men Harbor More Aggressive Disease on Prostate Biopsy?. Urology, 2013, 81, 949-955.	0.5	21
187	Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases â€“ a medium term, prospective, randomized comparison. BJU International, 2013, 111, 793-803.	1.3	114
188	Outcome of GreenLight HPS laser therapy in surgically high-risk patients. Lasers in Medical Science, 2013, 28, 1297-1303.	1.0	10
189	Salvage Combination Intravesical Immunotherapy With Bacillus Calmette-GuÃ©rin and Interferon-Î±2B: Impact on Recurrence, Progression, and Survival. Hospital Practice (1995), 2013, 41, 31-39.	0.5	5
190	Technical Aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia. Korean Journal of Urology, 2013, 54, 570.	1.2	56
191	Editorial Comment. Scandinavian Journal of Urology, 2013, 47, 196-197.	0.6	0
192	Obesity and Future Prostate Cancer Risk among Men after an Initial Benign Biopsy of the Prostate. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 898-904.	1.1	20
193	Twelve-Month Follow-up Results of Photoselective Vaporization of the Prostate With a 980-nm Diode Laser for Treatment of Benign Hyperplasia. Korean Journal of Urology, 2013, 54, 677.	1.2	10
194	Body mass index influences prostate cancer risk at biopsy in <scp>J</scp>apanese men. International Journal of Urology, 2013, 20, 701-707.	0.5	16
195	Analysis of the Anatomical Characteristics of the Pelvis in Koreans to Aid in Development of a NOTES Platform. Surgical Innovation, 2013, 20, 134-141.	0.4	5

#	Article	IF	Citations
196	Ageâ€stratified outcomes of holmium laser enucleation of the prostate. BJU International, 2013, 112, 982-989.	1.3	36
197	Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males. Clinical Interventions in Aging, 2013, 8, 1483.	1.3	14
198	Relationship of Postoperative Recatheterization and Intraoperative Bladder Distention Volume in Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia. Korean Journal of Urology, 2013, 54, 89.	1.2	3
199	The Current Role of the Artificial Urinary Sphincter in Male and Female Urinary Incontinence. World Journal of Men?s Health, 2013, 31, 21.	1.7	17
200	Factors Affecting De Novo Urinary Retention after Holmium Laser Enucleation of the Prostate. PLoS ONE, 2014, 9, e84938.	1.1	13
201	Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Canadian Urological Association Journal, 2014, 8, 306.	0.3	30
202	Re-examination of the Natural History of High-grade T1 Bladder Cancer using a Large Contemporary Cohort. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 172-178.	0.7	8
203	An Analytical Comparison of Short-term Effectiveness and Safety Between Thulium:YAG Laser Vaporesection of the Prostate and Bipolar Transurethral Resection of the Prostate in Patients With Benign Prostatic Hyperplasia. Korean Journal of Urology, 2014, 55, 41.	1.2	14
204	Obesity is associated with higher risk of prostate cancer detection in a biopsy population in <scp>K</scp>orea. BJU International, 2014, 114, 891-895.	1.3	30
205	Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status. Korean Journal of Urology, 2014, 55, 249.	1.2	2
206	Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer. Urology Annals, 2014, 6, 273.	0.3	1
207	Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer. Urology Annals, 2014, 6, 305.	0.3	18
208	Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. Molecular and Clinical Oncology, 2014, 2, 575-580.	0.4	27
209	New agents for bacillus Calmetteâ€“GuÃ©rin-refractory nonmuscle invasive bladder cancer. Current Opinion in Urology, 2014, 24, 540-545.	0.9	12
210	Male LUTS/BPH Made Easy. , 2014, , .		0
211	Association of Prostate Size and Perioperative Morbidity in Thulium:YAG Vapoenucleation of the Prostate. Urologia Internationalis, 2014, 93, 22-28.	0.6	24
212	Holmium laser enucleation of the prostate: a review of the clinical trial evidence. Therapeutic Advances in Urology, 2014, 6, 62-73.	0.9	17
213	Efficacy of Holmium Laser Enucleation of the Prostate in Patients With Non-neurogenic Impaired Bladder Contractility: Results of a Prospective Trial. Urology, 2014, 83, 428-432.	0.5	57

#	Article	IF	Citations
214	Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. Journal of Urology, 2014, 191, 20-27.	0.2	98
215	Long-term outcome following Thulium VapoEnucleation of the prostate. World Journal of Urology, 2014, 32, 1551-1558.	1.2	43
216	Conceptualizing global health-related quality of life in bladder cancer. Quality of Life Research, 2014, 23, 2153-2167.	1.5	16
217	Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study. Japanese Journal of Clinical Oncology, 2014, 44, 1101-1108.	0.6	6
218	Holmium Laser Enucleation of the Prostate Is Safe in Patients with Prostate Cancer and Lower Urinary Tract Symptomsâ€"A Retrospective Feasibility Study. Journal of Endourology, 2014, 28, 335-341.	1.1	16
219	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	1.1	84
220	Thulium laser (<scp>RevoLix</scp>) vaporesection versus vapoenucleation with morcellator (<scp>P</scp>iranha) for the treatment of benign prostatic obstruction: A propensityâ€matched multicenter analysis. International Journal of Urology, 2014, 21, 1156-1161.	0.5	10
221	Did prostate size affect the complication and outcome of plasmakinetic enucleation of the prostate?. International Urology and Nephrology, 2014, 46, 2063-2070.	0.6	6
222	Plasmakinetic Enucleation of the Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: Comparison of Outcomes According to Prostate Size in 310 Patients. Urology, 2014, 84, 904-910.	0.5	33
223	Association Between Use of Î²-Blockers and Prostate Cancerâ€"Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. European Urology, 2014, 65, 635-641.	0.9	197
224	Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e1-40.e8.	0.8	27
225	Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy. International Journal of Urology, 2014, 21, 52-57.	0.5	29
226	Screening for Prostate Cancer: New Markers and Future Aspects. , 2014, , 541-568.		0
227	Prognostic effect of preoperative anemia in patients who have undergone radical cystectomy for bladder cancer. Cancer Treatment Communications, 2015, 4, 196-199.	0.4	4
228	Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. Current Opinion in Urology, 2015, 25, 427-435.	0.9	27
229	Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?. Bladder Cancer, 2015, 2, 1-14.	0.2	6
230	Bacillus Calmette-GuÃ©rin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. Bladder Cancer, 2015, 1, 105-116.	0.2	13
231	Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-GuÃ©rin. Molecular and Clinical Oncology, 2015, 3, 1113-1116.	0.4	7

#	Article	IF	Citations
232	Efficacy and safety of holmium laser enucleation of the prostate for extremely large prostatic adenoma in patients with benign prostatic hyperplasia. Korean Journal of Urology, 2015, 56, 218.	1.2	23
233	Reoperation After Holmium Laser Enucleation of the Prostate for Management of Benign Prostatic Hyperplasia: Assessment of Risk Factors with Time to Event Analysis. Journal of Endourology, 2015, 29, 797-804.	1.1	52
234	Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?. Japanese Journal of Clinical Oncology, 2015, 45, 315-322.	0.6	14
235	Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction. Urology, 2015, 86, 133-138.	0.5	13
236	Prostate cancer detection: The impact of obesity on Asian men. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 266.e17-266.e22.	0.8	12
238	Intravesical therapy for bladder cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 889-901.	0.9	26
239	Homely holmium. Nature Chemistry, 2015, 7, 532-532.	6.6	1
240	En-Bloc Technique With Anteroposterior Dissection Holmium Laser Enucleation of the Prostate Allows a Short Operative Time and Acceptable Outcomes. Urology, 2015, 86, 628-633.	0.5	34
242	Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. International Journal of Impotence Research, 2015, 27, 20-24.	1.0	46
243	Prognostic Factors and Risk Groups in T1G3 Nonâ€“Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-GuÃ©rin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	0.9	190
244	Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?. Archivio Italiano Di Urologia Andrologia, 2016, 88, 13.	0.4	9
245	Bacillus Calmette-GuÃ©rin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer, 2016, 2, 215-224.	0.2	32
246	Prostateâ€specific antigen lowering effect of metabolic syndrome is influenced by prostate volume. International Journal of Urology, 2016, 23, 299-304.	0.5	6
248	Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Nonâ€“Muscle-Invasive Bladder Cancer. Cancer Prevention Research, 2016, 9, 437-444.	0.7	19
249	Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations. International Journal of Hyperthermia, 2016, 32, 363-373.	1.1	29
250	p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World Journal of Surgical Oncology, 2016, 14, 137.	0.8	27
252	Essential content of evidenceâ€based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update. International Journal of Urology, 2016, 23, 640-645.	0.5	30
254	Holmium laser enucleation versus simple prostatectomy for treating large prostates: Results of a systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2016, 14, 50-58.	0.7	65

#	Article	IF	Citations
255	Prostate-specific Antigen Mass Densityâ€"A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. Urology, 2016, 90, 141-147.	0.5	11
256	Definitions, End Points, and Clinical Trial Designs for Nonâ€"Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. Journal of Clinical Oncology, 2016, 34, 1935-1944.	0.8	279
257	Analysis of Benign Prostatic Hyperplasia Patients' Perspective Through a Third Party-administered Survey. Urology, 2016, 88, 155-160.	0.5	11
258	The en-bloc no-touch holmium laser enucleation of the prostate (HoLEP) technique. World Journal of Urology, 2016, 34, 1175-1181.	1.2	79
260	Toward Improving Transurethral Prostate Surgery: Development and Initial Experiments with a Prototype Concentric Tube Robotic Platform. Journal of Endourology, 2016, 30, 692-696.	1.1	15
261	Characterizing intermediate-risk nonâ€"muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 208-214.	0.8	5
262	Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. Urology, 2017, 105, 129-135.	0.5	16
264	Tackling non-muscle invasive bladder cancer in the clinic. Expert Review of Anticancer Therapy, 2017, 17, 467-480.	1.1	11
265	Complications of laser enucleation of the prostate: Results at two institutions. Urological Science, 2017, 28, 223-226.	0.2	0
266	Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk. Prostate, 2017, 77, 949-954.	1.2	12
267	A New Laser Platform for Holmium Laser Enucleation of the Prostate: Does the Lumenis Pulse 120H Laser Platform Improve Enucleation Efficiency?. Urology, 2017, 102, 198-201.	0.5	11
268	Targeting Inflammation for Bladder Cancer Chemoprevention. Current Pharmacology Reports, 2017, 3, 447-457.	1.5	1
269	Ã‰nuclÃ©ation prostatique au laser holmium (HoLEP)ÂÂ«Âen blocÂÂ». ProgrÃ¨s En Urologie - FMC, 2017, 27, F71-F74.	0.2	1
270	Efficacy of holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction (BOO) and nonâ€neurogenic bladder dysfunction. Kaohsiung Journal of Medical Sciences, 2017, 33, 458-463.	0.8	10
271	Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease. Scientific Reports, 2017, 7, 4630.	1.6	24
272	Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study. International Journal of Clinical Oncology, 2017, 22, 353-358.	1.0	17
273	Does Cystolitholapaxy at the Time of Holmium Laser Enucleation of the Prostate Affect Outcomes?. Urology, 2017, 99, 192-196.	0.5	17
276	Measuring change in prostate size after holmium laser enucleation: A prospective study. Investigative and Clinical Urology, 2017, 58, 200.	1.0	5

#	Article	IF	Citations
277	Immunotherapy of transitional cell carcinoma of urinary bladder. Medicina, 2017, 53, 314-319.	0.0	0
278	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	0.9	8
279	Obesity suppresses tumor attributable PSA, affecting risk categorization. Endocrine-Related Cancer, 2018, 25, 561-568.	1.6	5
280	Innovative endoscopic enucleations of the prostate â€“ Xie's Prostate Enucleations. Asian Journal of Urology, 2018, 5, 12-16.	0.5	2
281	Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate. Lasers in Medical Science, 2018, 33, 589-595.	1.0	2
282	Indication for early cystectomy in nonmuscle-invasive bladder cancer. Literature review. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 17-24.	0.2	1
283	Surgical Treatment: Transurethral Resection of theÂProstate. , 2018, , 117-128.		0
284	Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmetteâ€“GuÃ©rin Therapy. Annals of Surgical Oncology, 2018, 25, 2484-2491.	0.7	27
285	Comparison of Vela and holmium laser enucleation of the prostate: a retrospective clinical trial with a 12-month follow-up. International Urology and Nephrology, 2018, 50, 819-823.	0.6	6
286	Does switching the bacillus Calmette-GuÃ©rin strain affect clinical outcome in patients with recurrent nonâ€“muscle-invasive bladder cancer after initial bacillus Calmette-GuÃ©rin therapy?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 306.e1-306.e8.	0.8	2
287	Upper tract urothelial carcinoma following intravesical bacillus Calmette-GuÃ©rin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 306.e9-306.e15.	0.8	14
288	Implementing risk-aligned bladder cancer surveillance care. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 257-264.	0.8	18
289	IndicaciÃ³n de cistectomÃa precoz en el cÃ¡ncer vesical no mÃºsculo infiltrante. RevisiÃ³n de la literatura. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 17-24.	0.3	7
290	New Surgical Instruction Method for Homium Laser Enucleation of the Prostate, â€œHandâ€Grab Navigated Technique,â€•to Shorten the Learning Curve: <scp>T</scp>he Results of Multicenter Analysis. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 247-252.	0.6	4
292	T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate. Translational Andrology and Urology, 2018, 7, S692-S695.	0.6	2
293	Understanding risk and refining surveillance following tumor resection for low grade non-muscle invasive bladder cancer. Translational Andrology and Urology, 2018, 7, 987-989.	0.6	1
294	Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer. JAMA Network Open, 2018, 1, e183442.	2.8	18
295	Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 267-272.	0.7	11

#	Article	IF	Citations
296	Influence of prostate size on the perioperative and postoperative outcome of transurethral plasmakinetic enucleation of the prostate: Results of 892 patients with 3 years of followâ€up. Kaohsiung Journal of Medical Sciences, 2018, 34, 576-582.	0.8	5
297	ASO Author Reflections: PD-1 Expression in Bacillus Calmetteâ€“GuÃ©rin-Relapsing Bladder Cancer. Annals of Surgical Oncology, 2018, 25, 982-983.	0.7	0
298	Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-GuÃ©rin: A Retrospective Study. Urologia Internationalis, 2018, 101, 269-276.	0.6	11
299	A risk-stratified approach to the management of high-grade T1 bladder cancer. Current Opinion in Urology, 2018, 28, 563-569.	0.9	6
300	Second Transurethral Resection of Bladder Cancer. , 2018, , 255-261.		0
302	Treatment of Failure of Intravesical Therapy. , 2018, , 327-334.		0
303	Surgical Treatment for LUTS/BPH: Laser Devices. , 2018, , 257-288.		0
304	Holmium Enucleation of the Prostate. , 2018, , 73-79.		1
305	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	0.9	61
306	Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. Expert Opinion on Emerging Drugs, 2018, 23, 135-147.	1.0	10
307	â€œThree horse shoe-like incisionâ€•holmium laser enucleation of the prostate: first experience with a novel en bloc technique for anatomic transurethral prostatectomy. World Journal of Urology, 2019, 37, 523-528.	1.2	28
308	Association of Low Socioeconomic Status With Adverse Prostate Cancer Pathology Among African American Men Who Underwent Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, e1054-e1059.	0.9	9
309	Factors Influencing Intraoperative Blood Loss in Patients Undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: A Large Multicenter Analysis. Urology, 2019, 132, 177-182.	0.5	19
310	Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmetteâ€“GuÃ©rin immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2131-2140.	1.2	5
312	BCG for the Treatment of Non-muscle Invasive Bladder Cancer. , 2019, , 103-118.		0
313	Thulium vapoenucleation of the prostate (ThuVEP) for prostates larger than 85Âml: long-term durability of the procedure. Lasers in Medical Science, 2019, 34, 1637-1643.	1.0	11
314	Effect of preoperative urethral dilatation on preventing urethral stricture after holmium laser enucleation of the prostate: A randomized controlled study. Canadian Urological Association Journal, 2019, 13, E357-E360.	0.3	2
315	Comparison of the Efficacy of Holmium Laser Enucleation of the Prostate in Treating Prostate Volumes of â‰80 and > 80 mL. Urologia Internationalis, 2019, 102, 306-310.	0.6	14

#	Article	IF	Citations
316	Bacillus Calmette-GuÃ©rin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 17-30.	3.9	20
317	Staging of bladder cancer. Histopathology, 2019, 74, 112-134.	1.6	117
318	The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World Journal of Urology, 2019, 37, 2041-2049.	1.2	21
319	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
320	How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-GuÃ©rin?. European Urology Oncology, 2020, 3, 252-257.	2.6	1
321	Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30â€“80 and 80â€“150ÂmL prostates. BJU International, 2020, 125, 112-122.	1.3	24
322	Bacillus Calmetteâ€“GuÃ©rinâ€unresponsive nonâ€muscleâ€invasive bladder cancer: Its definition and future therapeutic strategies. International Journal of Urology, 2020, 27, 108-116.	0.5	22
323	Holmium laser enucleation of the prostate in Jehovahâ€™s Witness patients. International Urology and Nephrology, 2020, 52, 455-460.	0.6	2
324	Salvage Therapies for Nonâ€“muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-GuÃ©rin? Predictors and Nomograms. Urologic Clinics of North America, 2020, 47, 5-13.	0.8	1
325	Identification of Candidates for Salvage Therapy. Urologic Clinics of North America, 2020, 47, 15-21.	0.8	2
326	Minimally Invasive Urology. , 2020, , .		0
327	The International Continence Society (ICS) report on the terminology for male lower urinary tract surgery. Neurourology and Urodynamics, 2020, 39, 2072-2088.	0.8	6
328	Understanding Regional Risk Factors for Cancer: A Cluster Analysis of Lifestyle, Environment and Socio-Economic Status in Poland. Sustainability, 2020, 12, 9080.	1.6	4
329	Considerations about Non-Metastatic Bladder Cancer Management During the COVID-19 Pandemic. Bladder Cancer, 2020, 6, 99-106.	0.2	1
330	The low power effect on holmium laser enucleation of prostate (HoLEP); A comparison between 20 W and 37,5 W energy regarding apical enucleation efficacy and patient safety. Progres En Urologie, 2020, 30, 632-638.	0.3	3
331	Nuevas inmunoterapias en el cÃ¡ncer de vejiga no mÃºsculo-invasivo de alto riesgo: estado actual y perspectivas de futuro. Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 574-585.	0.3	3
332	New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 574-585.	0.2	1
333	Complications of anatomical endoscopic enucleation of the prostate. Andrologia, 2020, 52, e13557.	1.0	8

#	Article	IF	Citations
334	A rare case of synchronous bilateral epididymal and testicular metastases of urothelial carcinoma of the bladder after intravesical bacillus Calmetteâ€“GuÃ©rin. International Cancer Conference Journal, 2021, 10, 59-62.	0.2	2
335	The clinical value of holmium laser enucleation of the prostate in octogenarians. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 279-285.	0.6	28
336	â€˜Top-Downâ€™ holmium laser enucleation of the prostate. Report of initial cases performed by a single surgeon. Arab Journal of Urology Arab Association of Urology, 2021, 19, 130-136.	0.7	2
337	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer and Prostatic Diseases, 2021, 24, 253-260.	2.0	6
338	A prospective study on the association between post-voiding residual volume and quality of life during bacille Calmette-GuÃ©rin (BCG) instillation therapy for nonâ€“muscle-invasive bladder cancer. Journal of Clinical Urology, 2021, 14, 255-261.	0.1	0
339	Classification and Treatment Options for BCG-Failure. Advances in Clinical Medicine, 2021, 11, 4255-4262.	0.0	0
340	The potential diagnosis role of TP53 mutation in advanced bladder cancer: A metaâ€analysis. Journal of Clinical Laboratory Analysis, 2021, 35, e23765.	0.9	8
341	Clinical outcomes after intravesical bacillus Calmetteâ€“GuÃ©rin for the highestâ€risk nonâ€muscleâ€invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. International Journal of Urology, 2021, 28, 720-726.	0.5	5
342	The Implementation of a Risk Stratification Tool for the Haematuria Clinic to Optimise the Management of Patients with High-Risk Bladder Cancer in the COVID-19 Era. Journal of Endoluminal Endourology, 2021, 4, e20-e27.	0.2	0
343	T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram. Frontiers in Surgery, 2021, 8, 704902.	0.6	5
344	Neoplasms of the urinary bladder. , 2008, , 258-351.		25
345	Nonâ€“Muscle-Invasive Bladder Cancer (Ta, T1, and CIS). , 2012, , 2335-2354.e8.		17
346	Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis. Indian Journal of Urology, 2008, 24, 61.	0.2	5
347	Intravesical therapy for urothelial carcinoma of the bladder. Indian Journal of Urology, 2011, 27, 252.	0.2	11
348	Saudi Oncology Society clinical management guidelines for urinary bladder cancer. Urology Annals, 2011, 3, 6.	0.3	2
349	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017. Urology Annals, 2018, 10, 133.	0.3	3
350	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal, 2016, 10, 46.	0.3	55
351	Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer?. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10401-10405.	0.5	4

#	Article	IF	Citations
353	Intravesical Chemotherapy. , 2011, , 253-270.		0
354	Treatment of Low-Grade Bladder Tumors. , 2011, , 237-252.		0
355	Infections in Solid Tumor Patients. , 2011, , 39-45.		0
356	Non-Muscle-Invasive Low- and High-Grade Neoplasia. , 2012, , 113-141.		0
357	EFFICACY OF SEQUENTIAL BCG AND MITOMYCIN VERSUS MITOMYCIN ALONE FOR TREATMENT OF SUPERFICIAL BLADDER CANCER. Basrah Journal of Surgery, 2012, 18, 102-111.	0.0	0
360	BCG for the Treatment of Non-muscle Invasive Bladder Cancer. , 2016, , 85-97.		0
362	Value of separate tumor base biopsy in transurethral resection of bladder tumors. Central European Journal of Urology, 2020, 73, 440-444.	0.2	1
363	Second-look TURBT: evaluation of anatomopatological and oncologic results in a single center. Acta Biomedica, 2020, 91, 322-325.	0.2	1
365	Do we need repeat <scp>transurethral resection</scp> after en bloc resection for <scp>pathological T1</scp> bladder cancer?. BJU International, 2023, 131, 190-197.	1.3	13
366	Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmetteâ€“GuÃ©rin instillation. Pathology, 2022, 54, 700-706.	0.3	0
367	Realâ€world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmetteâ€GuÃ©rin failure in nonâ€muscleâ€invasive bladder cancer. International Journal of Urology, 2022, 29, 1195-1203.	0.5	5
368	Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with Bacillus Calmetteâ€“GuÃ©rin. Cytotechnology, 0, , .	0.7	0
369	A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-GuÃ©rin in Patients with High-risk Nonâ€“muscle-invasive Bladder Cancer. European Urology Oncology, 2023, 6, 313-320.	2.6	6